文献速递心脑血管急症

急性缺血性卒中血管内治疗两年结局

Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke.
PubMed 文献 · N Engl J Med · 2017-01-01
一句话结论急性缺血性卒中血管内治疗2年功能结局仍优于常规治疗(校正共同OR 1.68,95%CI 1.15–2.45,P=0.007)。

该扩展随访研究评估急性缺血性卒中患者随机接受血管内治疗或常规治疗2年后的临床结局。主要终点为2年时改良Rankin量表评分,391例(78.2%)有2年数据,459例(91.8%)有死亡信息。改良Rankin量表结局分布 favoring 血管内治疗(校正共同OR 1.68,95%CI 1.15–2.45,P=0.007),生活质量平均分血管内治疗组0.48 vs 常规治疗组0.38(均差0.10,95%CI 0.03–0.16,P=0.006),2年累积死亡率26.0% vs 31.0%(校正HR 0.9,95%CI 0.6–1.2,P=0.46),无显著差异。作者结论认为血管内治疗对2年功能结局的获益与原始试验90天报告相似。

要点

  • 2年改良Rankin量表结局分布 favoring 血管内治疗(校正共同OR 1.68,95%CI 1.15–2.45,P=0.007)。
  • 2年生活质量平均分血管内治疗组0.48 vs 常规治疗组0.38(均差0.10,95%CI 0.03–0.16,P=0.006)。
  • 2年累积死亡率血管内治疗组26.0% vs 常规治疗组31.0%(校正HR 0.9,95%CI 0.6–1.2,P=0.46),无显著差异。
  • 极好结局(改良Rankin量表评分0或1)百分比两组无显著差异。
  • 500例随机化患者中391例(78.2%)有2年数据,459例(91.8%)有死亡信息。

适用人群与场景

  • 急性缺血性卒中患者,随机接受血管内治疗(干预组)或常规治疗(对照组)。

研究设计与关键结果

  • 研究类型:扩展随访试验(MR CLEAN试验的2年随访)。
  • 样本量:原始试验500例随机化,391例(78.2%)有2年数据,459例(91.8%)有死亡信息。
  • 主要终点:2年改良Rankin量表评分分布 favoring 血管内治疗(校正共同OR 1.68,95%CI 1.15–2.45,P=0.007)。
  • 次要终点:极好结局(改良Rankin量表评分0或1)百分比两组无显著差异;生活质量平均分血管内治疗组0.48 vs 常规治疗组0.38(均差0.10,95%CI 0.03–0.16,P=0.006);2年累积死亡率血管内治疗组26.0% vs 常规治疗组31.0%(校正HR 0.9,95%CI 0.6–1.2,P=0.46),无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的扩展随访。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:血管内治疗对2年功能结局的获益与原始试验90天报告相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Several trials involving patients with acute ischemic stroke have shown better functional outcomes with endovascular treatment than with conventional treatment at 90 days after initiation of treatment. However, results on long-term clinical outcomes are lacking.

METHODS: We assessed clinical outcomes 2 years after patients were randomly assigned to receive either endovascular treatment (intervention group) or conventional treatment (control group) for acute ischemic stroke. The primary outcome was the score on the modified Rankin scale at 2 years; this scale measures functional outcome, with scores ranging from 0 (no symptoms) to 6 (death). Secondary outcomes included all-cause mortality and the quality of life at 2 years, as measured by means of a health utility index that is based on the European Quality of Life-5 Dimensions questionnaire (scores range from -0.329 to 1, with higher scores indicating better health).

RESULTS: Of the 500 patients who underwent randomization in the original trial, 2-year data for this extended follow-up trial were available for 391 patients (78.2%) and information on death was available for 459 patients (91.8%). The distribution of outcomes on the modified Rankin scale favored endovascular treatment over conventional treatment (adjusted common odds ratio, 1.68; 95% confidence interval [CI], 1.15 to 2.45; P=0.007). There was no significant difference between the treatment groups in the percentage of patients who had an excellent outcome (i.e., a modified Rankin scale score of 0 or 1). The mean quality-of-life score was 0.48 among patients randomly assigned to endovascular treatment as compared with 0.38 among patients randomly assigned to conventional treatment (mean difference, 0.10; 95% CI, 0.03 to 0.16; P=0.006). The cumulative 2-year mortality rate was 26.0% in the intervention group and 31.0% in the control group (adjusted hazard ratio, 0.9; 95% CI, 0.6 to 1.2; P=0.46).

CONCLUSIONS: In this extended follow-up trial, the beneficial effect of endovascular treatment on functional outcome at 2 years in patients with acute ischemic stroke was similar to that reported at 90 days in the original trial. (Funded by the Netherlands Organization for Health Research and Development and others; MR CLEAN Current Controlled Trials number, ISRCTN10888758 , and Netherlands Trial Register number, NTR1804 , and MR CLEAN extended follow-up trial Netherlands Trial Register number, NTR5073 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. van den Berg LA, Dijkgraaf MG, Berkhemer OA, et al. Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke. N Engl J Med. 2017. PMID: 28379802. doi:10.1056/NEJMoa1612136

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。